Jillian Baker

Contact

• workRoom CS6 The University of Nottingham Medical School
  Queen's Medical Centre
  Nottingham
  NG7 2UH
  UK
• work0115 82 30085
• fax0115 82 30081
• jillian.baker@nottingham.ac.uk

Biography

After obtaining my medical degree from the University of Nottingham, I completed my Junior doctor training in Queen's Medical Centre, Nottingham City Hospital and Derbyshire Royal Infirmary. I then began Specialist Registrar training in Respiratory Medicine in Nottingham and was awarded a Wellcome Trust Clinical Training Fellowship to do a basic science PhD in Pharmacology in Nottingham under the supervision of Prof Steve Hill and Prof Ian Hall. Having obtained a PhD (2004), I found I loved both research and clinical medicine so much that I wanted to pursue a joint career. I was fortunate to be awarded a Wellcome Trust Clinician Scientist Fellowship (2004-2010) to continue my research whilst completing my clinical training. In 2010, I became an honorary Consultant in Respiratory Medicine in Queen's Medical Centre and in 2013 a Professor of Drug Discovery and Respiratory Medicine in the School of Life Sciences.

Expertise Summary

As a doctor working in the area of adult sleep and respiratory medicine in Queen's Medical Centre, Nottingham, I see first-hand many of the short-comings of some of our current drugs. For some medical conditions, we just do not have the right drugs. For other conditions the side-effects of our existing drugs cause problems for all, or some, of the people who take them. My research interests are therefore two-fold. Firstly, I am interested in the molecular pharmacology of GPCRs. These are the specialised docking sites on the outside of cells where certain hormones act (e.g. adrenaline), and where some drugs act (e.g. β-blockers for heart disease, and the blue inhalers used for asthma). My research is aimed at detailed scientific understanding of how these hormones and drugs interact with receptors to cause changes in the cell behaviour, and ultimately clinical benefit. Secondly, I combine my clinical and pharmacology knowledge to understand how clinical drugs act, why side effects occur, to help discover molecules without these side effects that have potential to become better future drugs, and to identify novel drugs for medical conditions with few treatment options. My ultimate aim is to improve clinical drug treatments for patients.

Selected Publications

• BAKER, J. G., 2005. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors British Journal of Pharmacology. VOL 144(NUMB 3), 317-322
• BAKER, J.G, HALL, I.P. and HILL, S.J., 2003. Agonist actions of "beta-blockers" provide evidence for two agonist activation sites or conformations of the human beta1-adrenoceptor Molecular Pharmacology. 63(6), 1312-1321
• BAKER, J.G., HALL, I.P. and HILL, S.J., 2003. Influence of agonist efficacy and receptor phosphorylation on antagonist affinity measurements: differences between second messenger and reporter gene responses Molecular Pharmacology. 64(3), 679-688
• BAKER, J.G, 2005. Evidence for a secondary state of the human beta3-adrenoceptor. Molecular Pharmacology. 68(6), 1645-1655

• View all publications

• CORREA, MICHELLE FIDELIS, RAMOS BARBOSA, ALEFE JHONATAS, BORGES FERNANDES, GUSTAVO ARIEL, BAKER, JILLIAN G. and DOS SANTOS FERNANDES, JOAO PAULO, 2019. Pharmacological and SAR analysis of the LINS01 compounds at the human histamine H-1, H-2, and H-3 receptors CHEMICAL BIOLOGY & DRUG DESIGN. 93(1), 89-95
• BAKER JG, GARDINER SM, WOOLARD J, FROMONT C, JADHAV GP, MISTRY SN, THOMPSON KS, KELLAM B, HILL SJ and FISCHER PM, 2017. Novel selective β1-adrenoceptor antagonists for concomitant cardiovascular and respiratory disease. FASEB Journal. 31(7), 3150-3166
• SCHMIDT D, GUNERA J, BAKER JG and KOLB P, 2017. Similarity- and Substructure-Based Development of β2-Adrenergic Receptor Ligands Based on Unusual Scaffolds. ACS medicinal chemistry letters. 8(5), 481-485
• BAKER JG and WILCOX RG, 2016. β-Blockers, heart disease and COPD: current controversies and uncertainties. Thorax. (In Press.)
• BAKER JG, PROUDMAN RGW and HILL SJ, 2015. Salmeterol's Extreme β2 Selectivity Is Due to Residues in Both Extracellular Loops and Transmembrane Domains. Molecular pharmacology. 87(1), 103-20
• GHERBI, KAROLINA, MAY, LAUREN T., BAKER, JILLIAN G., BRIDDON, STEPHEN J. and HILL, STEPHEN J., 2015. Negative cooperativity across beta(1)-adrenoceptor homodimers provides insights into the nature of the secondary low-affinity CGP 12177 beta(1)-adrenoceptor binding conformation FASEB JOURNAL. 29(7), 2859-2871
• SATO T, BAKER J, WARNE T, BROWN GA, LESLIE AG, CONGREVE M and TATE CG, 2015. Pharmacological Analysis and Structure Determination of 7-Methylcyanopindolol-Bound β1-Adrenergic Receptor. Molecular pharmacology. 88(6), 1024-34
• BAKER JG, PROUDMAN RGW and HILL SJ, 2014. Identification of key residues in transmembrane 4 responsible for the secondary, low-affinity conformation of the human β1-adrenoceptor. Molecular pharmacology. 85(5), 811-29
• MISTRY, S.N., BAKER, J.G., FISCHER, P.M., HILL, S.J., GARDINER, S.M. and KELLAM, B., 2013. Synthesis and in vitro and in vivo characterization of highly β₁-selective β-adrenoceptor partial agonists Journal of Medicinal Chemistry. 56(10), 3852-3865
• BAKER JG, PROUDMAN RGW and HILL SJ, 2013. Impact of polymorphic variants on the molecular pharmacology of the two-agonist conformations of the human β1-adrenoceptor. PloS one. 8(11), e77582
• WARNE, T., MOUKHAMETZIANOV, R., BAKER, J.G., NEHMÉ, R., EDWARDS, P.C., LESLIE, A.G.W., SCHERTLER, G.F.X. and TATE, C.G., 2011. The structural basis for agonist and partial agonist action on a β1-adrenergic receptor. Nature. 469(7329), 241-244
• BAKER, J.G., ADAMS, L.A., SALCHOW, K., MISTRY, S.N., MIDDLETON, R.J., HILL, S.J. and KELLAM, B., 2011. Synthesis and characterization of high-affinity 4,4-difluoro-4-bora-3A,4A-diaza-s-indacene-labeled fluorescent ligands for human β-adrenoceptors Journal of Medicinal Chemistry. 54(19), 6874-6887
• JILLIAN G BAKER, RICHARD GW PROUDMAN and CHRISTOPHER G TATE, 2011. The pharmacological effects of the thermostabilising (m23) mutations and intra and extracellular (β36) deletions essential for crystallisation of the turkey β-adrenoceptor NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY. 384, 71-91
• BAKER, J.G., KEMP, P., MARCH, J., FRETWELL, L., HILL, S.J. and GARDINER, S.M., 2011. Predicting in vivo cardiovascular properties of β-blockers from cellular assays: a quantitative comparison of cellular and cardiovascular pharmacological responses FASEB Journal. 25(12), 4486-4497
• JILLIAN G BAKER, STEPHEN J HILL and ROGER J SUMMERS, 2011. Evolution of β-blockers - from anti-anginal drugs to ligand-directed signalling TRENDS IN PHARMACOLOGICAL SCIENCES. 32, 227-234
• BAKER, J.G., MIDDLETON, R., ADAMS, L., MAY, L.T., BRIDDON, S.J., KELLAM, B. and HILL, S.J., 2010. Influence of fluorophore and linker composition on the pharmacology of fluorescent adenosine A₁ receptor ligands British Journal of Pharmacology. 159(4), 772-786
• BAKER, J.G., 2010. The selectivity of β-adrenoceptor agonists at human β₁-, β₂- and β₃-adrenoceptors British Journal of Pharmacology. 160(5), 1048-1061
• BAKER JG, 2010. A full pharmacological analysis of the three turkey β-adrenoceptors and comparison with the human β-adrenoceptors PLoS ONE. 5(11):, e15487. doi:10.1371/journal.pone.0015487
• BAKER, J.G., PROUDMAN, R.G.W., HAWLEY, N.C., FISCHER, P.M. and HILL, S.J., 2008. Role of key transmembrane residues in agonist and antagonist actions at the two conformations of the human β1-adrenoceptor Molecular Pharmacology. 74(5), 1246-1260
• BAKER, J G, 2008. A study of antagonist affinities for the human histamine H2 receptor. British Journal of Pharmacology. 153(5), 1011-21
• WARNE, T., SERRANO-VEGA, M.J., BAKER, J.G., MOUKHAMETZIANOV, R., EDWARDS, P.C., HENDERSON, R., LESLIE, A.G.W., TATE, C.G. and SCHERTLER, G.F.X., 2008. Structure of a β1-adrenergic G-protein-coupled receptor Nature. 454(7203), 486-491
• BAKER, JILLIAN G, 2008. Antagonist affinity measurements at the Gi-coupled human histamine H3 receptor expressed in CHO cells. BMC pharmacology. 8, 9
• MIDDLETON,R, BRIDDON,S.J., CORDEAUX,Y., YATES,A.S., DALE,C.L., GEORGE,M., BAKER,J.G., HILL,S.J. and KELLAM,B., 2007. New Fluorescent Adenosine A(1)-Receptor Agonists That Allow Quantification of Ligand-Receptor Interactions in Microdomains of Single Living Cells. Journal of Medicinal Chemistry. 50(4), 782-793
• BAKER, J.G. and HILL, S.J., 2007. A comparison of the antagonist affinities for the Gi and Gs-coupled states of the human adenosine A1 receptor Journal of Pharmacology and Experimental Therapeutics. 320(1), 218-228
• BAKER, JILLIAN G and HILL, STEPHEN J, 2007. Multiple GPCR conformations and signalling pathways: implications for antagonist affinity estimates. Trends in Pharmacological Sciences. 28(8), 374-81
• BAKER, J.G, 2005. Evidence for a secondary state of the human beta3-adrenoceptor. Molecular Pharmacology. 68(6), 1645-1655
• BAKER, J.G, 2005. Site of action of beta-ligands at the human beta1-adrenoceptor. Journal of Pharmacology and Experimental Therapeutics. 313(3), 1163-1171
• BAKER, J. G., 2005. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors British Journal of Pharmacology. VOL 144(NUMB 3), 317-322
• BAKER, J.G., HALL, I.P. and HILL, S.J., 2004. Temporal characteristics of cAMP response element-mediated gene transcription: requirement for sustained cAMP production Molecular Pharmacology. 65(4), 986-998
• BAKER, J.G, HALL, I.P. and HILL, S.J., 2003. Agonist actions of "beta-blockers" provide evidence for two agonist activation sites or conformations of the human beta1-adrenoceptor Molecular Pharmacology. 63(6), 1312-1321
• BAKER, J.G., HALL, I.P. and HILL, S.J., 2003. Agonist and inverse agonist actions of beta-blockers at the human beta 2-adrenoceptor provide evidence for agonist-directed signaling Molecular Pharmacology. 64(6), 1357-1369
• BAKER, J.G., HALL, I.P. and HILL, S.J., 2003. Influence of agonist efficacy and receptor phosphorylation on antagonist affinity measurements: differences between second messenger and reporter gene responses Molecular Pharmacology. 64(3), 679-688
• BAKER, J.G., HALL, I.P. and HILL, S.J., 2003. Pharmacology and direct visualisation of BODIPY-TMR-CGP: a long-acting fluorescent beta2-adrenoceptor agonist British Journal of Pharmacology. 139(2), 232-42
• HILL, S.J. and BAKER, J.G., 2003. The ups and downs of Gs- to Gi-protein switching British Journal of Pharmacology. 138(7), 1188-1190
• BAKER, J.G, HALL, I.P and HILL, S.J., 2002. Pharmacological characterization of CGP 12177 at the human beta(2)-adrenoceptor British Journal of Pharmacology. 137(3), 400-8
• HILL, S J, BAKER, J G and REES, S, 2001. Reporter-gene systems for the study of G-protein-coupled receptors. Current Opinion in Pharmacology. 1(5), 526-32